About M. Dror Michaelson, MD, PhD

Clinical Interests:

Treats:

Locations

Mass General Cancer Center: Hematology Oncology
55 Fruit St.
Boston, MA 02114
Phone: 617-726-1594
Phone: 617-724-4000
Fax: 617-726-3440

Mass General Cancer Center in Waltham
52 Second Ave.
Suite 1110
Waltham, MA 02451
Phone: 781-487-6100

Medical Education

  • MDPhD, Jacobi Medical Center
  • Residency, Brigham and Women's Hospital
  • Fellowship, Massachusetts General Hospital

American Board Certifications

  • Medical Oncology, American Board of Internal Medicine

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Research

At Mass General, we have participated in a number of crucial clinical trials that have shifted treatment in kidney cancer to targeted therapy with inhibition of angiogenesis. These trials have broadly impacted treatment of this disease and resulted in regulatory approval of new drugs including sunitinib. Dr. Michaelson has served on scientific advisory boards for a number of companies with an interest in developing targeted therapy for RCC, is a member of the NCCN Renal/Testicular Cancer Guidelines Panel, and also serves on the NCI RCC Task Force that is responsible for evaluating and modifying new clinical trial concepts. He currently leads and participates in phase 1 and phase 2 studies in RCC that hope to define tailored therapy for particular patient subpopulations in the move toward individualized cancer treatment. Regarding prostate cancer research, Dr. Michaelson has led an effort at Mass General and DFCI to characterize the activity of targeted therapy with sunitinib in men with advanced prostate cancer, and serves as the study chair for an international phase 3 trial in this patient population. Additionally, he has designed a phase 3 National Cancer Institute trial concept with a promising, novel hormonal agent in early high-risk prostate cancer. He also designed and leads a phase 1/2 NCI-sponsored cooperative group trial looking at combination of chemotherapy and targeted treatment together with radiation therapy in invasive bladder transitional cell carcinoma. Many of the efforts described above have been supported by peer-reviewed grants from the National Cancer Institute and Department of Defense, in addition to institutional sources.

Reviews: Comments and Ratings

4.9out of 5(217 Ratings, 98 Comments)

December 2024

Excellent care and friendly manner


December 2024

Certainly good, well prepared, engaging.


December 2024

The only comment I would make is that I thought it was very, certainly was very businesslike, which it should be. I didn't really get a full feeling of compassion that would have been nice to somehow put into the meeting that we had.


December 2024

Exceptional caring and providing Doctor


December 2024

The doctor Michaelson, he was awesome. I really appreciate everything he explained to me and the way he treats me. He's a great doctor. It's the second time I've seen him, and I'm very, very, very happy. Thank you.


December 2024

I am very satisfied with the care I receive from Dr Michaelson.


December 2024

Very Pleased.


December 2024

Prompt, professional, courteous


December 2024

I was extremely pleased with Dr. Michaelson. I had an uncomfortable situation to have to go in there dealing with cancer and he made me very, very comfortable laying out all the options, talking through the opportunities, and making sure that I was not only guided, but also comfortable with all the options I had. So I was extremely comfortable ... Read More


December 2024

My visit with Dr Michaelson was one of the effective and pleasant. He was attentive and patient with me answering questions and was pleasant and put me at ease regarding my condition and the recommended treatment process. His staff was also friendly and supportive.

View More
Ratings and Comments Powered by NRC Health